Jessica M. Peirce
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jessica M. Peirce has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
Robert K. Brooner
Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
9 shared publications- Michael Kidorf
Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA
5 shared publications - Rebecca L. Schacht
Department of Psychology, University of Maryland, Baltimore County, Baltimore, Maryland, USA
5 shared publications Ken Kolodner
Johns Hopkins University School of Medicine Baltimore MD USA
4 shared publicationsMichael S. Kidorf
Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Mason F. Lord 6 East, 5200 Eastern Avenue, Baltimore, MD 21224, United States
4 shared publicationsVan L. King
Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Mason F. Lord 6 East, 5200 Eastern Avenue, Baltimore, MD 21224, United States
4 shared publications
Latest Publications
- 22 February 2021
- Published by Taylor & Francis in Substance Use & Misuse
- Vol. 56 (4) , 546-551
Reducing Risky Drug Use Behaviors by Enrolling Syringe Exchange Registrants in Methadone Maintenance
Referral of syringe exchange registrants with opioid use disorder to agonist treatment provides a pathway to further reduce drug use risk behaviors. Objective: This study evaluates the drug use risk reduction benefits of enrolling syringe exchange registrants in methadone maintenance, and the impact of continued illicit drug use on risk reduction. Method: Baltimore Needle Exchange Program (BNEP) registrants (n = 210) participated in a parent study evaluating treatment initiation strategies for methadone maintenance and were followed for six months. The Risk Assessment Battery (RAB; Metzger, 1993 Metzger, D. (1993). The Risk Assessment Battery (RAB): Validity and reliability. In Presented at the annual meeting of the National Cooperative Vaccine Development Group for AIDS. Alexandria, VA: Alcohol and Drug Abuse Institute, University of Washington. [Google Scholar] ) was administered monthly to evaluate drug use risks; urinalysis testing was conducted weekly. Results: Treatment enrollment reduced drug use risk behaviors, and longer treatment episodes resulted in additional, though modest, risk reduction. Use of opioids or cocaine in treatment diminished risk-reduction benefits, though drug use risks declined over time and remained well below baseline levels. Conclusions: These findings demonstrate that methadone maintenance enhances the well-known risk-reduction benefits of syringe exchange participation. Improving coordination between syringe exchanges and treatment facilities may enhance the public health.
- 22 February 2021
- Published by Taylor & Francis in Substance Use & Misuse
- Vol. 56 (4) , 546-551
Reducing Risky Drug Use Behaviors by Enrolling Syringe Exchange Registrants in Methadone Maintenance
Referral of syringe exchange registrants with opioid use disorder to agonist treatment provides a pathway to further reduce drug use risk behaviors. Objective: This study evaluates the drug use risk reduction benefits of enrolling syringe exchange registrants in methadone maintenance, and the impact of continued illicit drug use on risk reduction. Method: Baltimore Needle Exchange Program (BNEP) registrants (n = 210) participated in a parent study evaluating treatment initiation strategies for methadone maintenance and were followed for six months. The Risk Assessment Battery (RAB; Metzger, 1993 Metzger, D. (1993). The Risk Assessment Battery (RAB): Validity and reliability. In Presented at the annual meeting of the National Cooperative Vaccine Development Group for AIDS. Alexandria, VA: Alcohol and Drug Abuse Institute, University of Washington. [Google Scholar] ) was administered monthly to evaluate drug use risks; urinalysis testing was conducted weekly. Results: Treatment enrollment reduced drug use risk behaviors, and longer treatment episodes resulted in additional, though modest, risk reduction. Use of opioids or cocaine in treatment diminished risk-reduction benefits, though drug use risks declined over time and remained well below baseline levels. Conclusions: These findings demonstrate that methadone maintenance enhances the well-known risk-reduction benefits of syringe exchange participation. Improving coordination between syringe exchanges and treatment facilities may enhance the public health.
- Open Access
- 9 January 2021
- Published by Elsevier in Journal of Substance Abuse Treatment
- Vol. 124, 108286
Sexual-risk reduction following the referral of syringe exchange registrants to methadone maintenance: Impact of gender and drug use
- 9 January 2021
- Published by Elsevier in Journal of Substance Abuse Treatment
- Vol. 124, 108286
Open AccessSexual-risk reduction following the referral of syringe exchange registrants to methadone maintenance: Impact of gender and drug use
- 29 June 2020
- Published by Wiley in Journal of Traumatic Stress
- Vol. 33 (4) , 465-476
The Effects of Prolonged Exposure on Substance Use in Patients With Posttraumatic Stress Disorder and Substance Use Disorders
Despite research demonstrating the benefit of exposure‐based therapy for posttraumatic stress disorder (PTSD) in patients with co‐occurring substance use disorders, there remains a strong clinical expectation that this treatment will exacerbate substance use or other psychiatric symptoms. The present study evaluated within‐session and session‐to‐session changes in (a) craving and use of substances for a range of drug classes and (b) symptoms of PTSD and other psychiatric distress in a sample of 44 SUD patients who received prolonged exposure (PE) therapy for PTSD. Visual analog scales showed no within‐session increases in craving, except for cocaine, within Session 8. Across sessions, craving scores dropped for heroin, methadone, benzodiazepines, and cocaine; no increases in craving were found. Past‐week substance use reported at each session did not differ. The severity of PTSD symptoms and self‐reported serious emotional problems decreased from Session 1 to subsequent sessions, with no increases or decreases in other psychiatric, social, or medical problems. Finally, PTSD severity was unrelated to substance use reported 1 or 2 weeks later. Substance use during the past week was associated with higher PTSD severity scores at the next session, B = 6.86 (SE = 2.87), p = .018, but was not associated 2 weeks later. These findings indicate that the concern that exposure therapy for PTSD will increase SUD patients’ substance use or other psychiatric symptoms may be unwarranted, and, thus, SUD patients, including those who are actively using, should have access to effective treatments for PTSD, like PE.
- 29 June 2020
- Published by Wiley in Journal of Traumatic Stress
- Vol. 33 (4) , 465-476
The Effects of Prolonged Exposure on Substance Use in Patients With Posttraumatic Stress Disorder and Substance Use Disorders
Despite research demonstrating the benefit of exposure‐based therapy for posttraumatic stress disorder (PTSD) in patients with co‐occurring substance use disorders, there remains a strong clinical expectation that this treatment will exacerbate substance use or other psychiatric symptoms. The present study evaluated within‐session and session‐to‐session changes in (a) craving and use of substances for a range of drug classes and (b) symptoms of PTSD and other psychiatric distress in a sample of 44 SUD patients who received prolonged exposure (PE) therapy for PTSD. Visual analog scales showed no within‐session increases in craving, except for cocaine, within Session 8. Across sessions, craving scores dropped for heroin, methadone, benzodiazepines, and cocaine; no increases in craving were found. Past‐week substance use reported at each session did not differ. The severity of PTSD symptoms and self‐reported serious emotional problems decreased from Session 1 to subsequent sessions, with no increases or decreases in other psychiatric, social, or medical problems. Finally, PTSD severity was unrelated to substance use reported 1 or 2 weeks later. Substance use during the past week was associated with higher PTSD severity scores at the next session, B = 6.86 (SE = 2.87), p = .018, but was not associated 2 weeks later. These findings indicate that the concern that exposure therapy for PTSD will increase SUD patients’ substance use or other psychiatric symptoms may be unwarranted, and, thus, SUD patients, including those who are actively using, should have access to effective treatments for PTSD, like PE.
- 1 July 2017
- Published by American Psychological Association (APA) in Journal of Consulting and Clinical Psychology
- Vol. 85 (7) , 689-701
Incentivizing attendance to prolonged exposure for PTSD with opioid use disorder patients: A randomized controlled trial.
To determine whether contingent monetary incentives increase opioid use disorder patients' attendance to Prolonged Exposure (PE) therapy and whether attendance is associated with improvement in posttraumatic stress disorder (PTSD) and substance use disorder (SUD) outcomes. Patients (N = 58) with PTSD were offered PE or PE with incentives (PE + I; max $480) to attend PE sessions. Participants were assessed at baseline and weeks 6, 12, and 24 postrandomization. Participants were mostly women (79%) and Caucasian (71%); mean age 37.43 years (SD = 11.33). PE + I participants attended a median of 9 (of 12) sessions compared to 1 session for PE participants (p < .001), which included more exposure sessions (PE + I mdn = 6; PE mdn = 0; p < .001). A Time × treatment condition interaction indicated that PE + I participants exhibited a greater decrease in PTSD severity over time than PE participants (OR = 3.1; 95% CI = 0.4-5.7; p = .024). PE + I participants remained in substance use treatment longer than PE participants (mdn days = 262 vs. 192; p = .039). There were no group differences in drug use. Monetary incentives increased SUD patients' attendance to an otherwise poorly attended treatment for PTSD. Better attendance in the incentivized group was associated with greater PTSD improvement, better SUD treatment retention, and no increased drug use. Incentives are well supported for improving adherence to substance use treatment goals and promising as a means to improve therapy attendance, which may improve the effectiveness of existing psychotherapies in difficult-to-treat populations. (PsycINFO Database Record
- 1 July 2017
- Published by American Psychological Association (APA) in Journal of Consulting and Clinical Psychology
- Vol. 85 (7) , 689-701
Incentivizing attendance to prolonged exposure for PTSD with opioid use disorder patients: A randomized controlled trial.
To determine whether contingent monetary incentives increase opioid use disorder patients' attendance to Prolonged Exposure (PE) therapy and whether attendance is associated with improvement in posttraumatic stress disorder (PTSD) and substance use disorder (SUD) outcomes. Patients (N = 58) with PTSD were offered PE or PE with incentives (PE + I; max $480) to attend PE sessions. Participants were assessed at baseline and weeks 6, 12, and 24 postrandomization. Participants were mostly women (79%) and Caucasian (71%); mean age 37.43 years (SD = 11.33). PE + I participants attended a median of 9 (of 12) sessions compared to 1 session for PE participants (p < .001), which included more exposure sessions (PE + I mdn = 6; PE mdn = 0; p < .001). A Time × treatment condition interaction indicated that PE + I participants exhibited a greater decrease in PTSD severity over time than PE participants (OR = 3.1; 95% CI = 0.4-5.7; p = .024). PE + I participants remained in substance use treatment longer than PE participants (mdn days = 262 vs. 192; p = .039). There were no group differences in drug use. Monetary incentives increased SUD patients' attendance to an otherwise poorly attended treatment for PTSD. Better attendance in the incentivized group was associated with greater PTSD improvement, better SUD treatment retention, and no increased drug use. Incentives are well supported for improving adherence to substance use treatment goals and promising as a means to improve therapy attendance, which may improve the effectiveness of existing psychotherapies in difficult-to-treat populations. (PsycINFO Database Record
- 1 January 2016
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 158, 126-131
Effect of traumatic event reexposure and PTSD on substance use disorder treatment response
- 1 January 2016
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 158, 126-131
Effect of traumatic event reexposure and PTSD on substance use disorder treatment response
- 1 November 2015
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 156, e175
Incentivizing attendance to prolonged exposure in methadone maintenance
- 1 November 2015
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 156, e175
Incentivizing attendance to prolonged exposure in methadone maintenance
- 1 January 2015
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 146, e159
Illicit drug use harms response to psychiatric treatment
- 1 January 2015
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 146, e159
Illicit drug use harms response to psychiatric treatment
- 20 February 2014
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 138, 98-102
Prospective risk factors for traumatic event reexposure in community syringe exchange participants.
- 20 February 2014
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 138, 98-102
Prospective risk factors for traumatic event reexposure in community syringe exchange participants.
Prospective effects of traumatic event re‐exposure and post‐traumatic stress disorder in syringe exchange participants
Aim: Determine the effect of traumatic event re‐exposure and post‐traumatic stress disorder (PTSD) symptom severity on proximal drug use and drug abuse treatment‐seeking in syringe exchange participants.Design: Prospective longitudinal 16‐month cohort study of new syringe exchange registrants enrolled in a parent study of methods to improve treatment engagement.Setting: Data were collected in a research van next to mobile syringe exchange distribution sites in Baltimore, Maryland.Participants: Male and female (n = 162) injecting drug users (IDUs) registered for syringe exchange.Measurements: Traumatic event re‐exposure was identified each month with the Traumatic Life Events Questionnaire. PTSD symptoms were measured with the Modified PTSD Symptom Scale–Revised, given every 4 months. Outcome measures collected monthly were days of drug use (heroin, cocaine) and drug abuse treatment‐seeking behavior (interest, calls to obtain treatment, treatment participation).Findings: Each traumatic event re‐exposure was associated with about 1 more day of cocaine use after accounting for the previous month's cocaine use [same month adjusted B, standard error = 1.16 (0.34); 1 month later: 0.99 (0.34)], while PTSD symptoms had no effect. Traumatic event re‐exposure increased interest in drug abuse treatment [same month adjusted odds ratios with 95% confidence intervals = 1.34 (1.11–1.63)] and calling to obtain treatment [same month 1.58 (1.24–2.01); 1 month later 1.34 (1.03–1.75)]. Each 10% increase in PTSD symptom severity was associated with persistent increased interest in treatment [same month 1.25 (1.10–1.42); 1 month later 1.16 (1.02–1.32); 2 months later 1.16 (1.02–1.32)] and calling to obtain treatment [same month 1.16 (1.02–1.32)]. Neither traumatic events nor PTSD symptoms were associated with participants receiving treatment.Conclusions: Becoming exposed again to traumatic events among injecting drug users is associated with an increase in cocaine use up to 1 month later, but drug use is not related to post‐traumatic stress disorder symptoms. Both traumatic event re‐exposure and post‐traumatic stress disorder symptoms predict drug abuse treatment‐seeking behavior for up to 2 months.
Prospective effects of traumatic event re‐exposure and post‐traumatic stress disorder in syringe exchange participants
Aim: Determine the effect of traumatic event re‐exposure and post‐traumatic stress disorder (PTSD) symptom severity on proximal drug use and drug abuse treatment‐seeking in syringe exchange participants.Design: Prospective longitudinal 16‐month cohort study of new syringe exchange registrants enrolled in a parent study of methods to improve treatment engagement.Setting: Data were collected in a research van next to mobile syringe exchange distribution sites in Baltimore, Maryland.Participants: Male and female (n = 162) injecting drug users (IDUs) registered for syringe exchange.Measurements: Traumatic event re‐exposure was identified each month with the Traumatic Life Events Questionnaire. PTSD symptoms were measured with the Modified PTSD Symptom Scale–Revised, given every 4 months. Outcome measures collected monthly were days of drug use (heroin, cocaine) and drug abuse treatment‐seeking behavior (interest, calls to obtain treatment, treatment participation).Findings: Each traumatic event re‐exposure was associated with about 1 more day of cocaine use after accounting for the previous month's cocaine use [same month adjusted B, standard error = 1.16 (0.34); 1 month later: 0.99 (0.34)], while PTSD symptoms had no effect. Traumatic event re‐exposure increased interest in drug abuse treatment [same month adjusted odds ratios with 95% confidence intervals = 1.34 (1.11–1.63)] and calling to obtain treatment [same month 1.58 (1.24–2.01); 1 month later 1.34 (1.03–1.75)]. Each 10% increase in PTSD symptom severity was associated with persistent increased interest in treatment [same month 1.25 (1.10–1.42); 1 month later 1.16 (1.02–1.32); 2 months later 1.16 (1.02–1.32)] and calling to obtain treatment [same month 1.16 (1.02–1.32)]. Neither traumatic events nor PTSD symptoms were associated with participants receiving treatment.Conclusions: Becoming exposed again to traumatic events among injecting drug users is associated with an increase in cocaine use up to 1 month later, but drug use is not related to post‐traumatic stress disorder symptoms. Both traumatic event re‐exposure and post‐traumatic stress disorder symptoms predict drug abuse treatment‐seeking behavior for up to 2 months.
- 12 October 2011
- Published by Springer Nature in Journal of Urban Health
- Vol. 89 (1) , 117-128
Traumatic Event Re-exposure in Injecting Drug Users
Drug users have very high rates of lifetime exposure to traumatic events, leading to significant psychiatric complications. In spite of the high rate of lifetime exposure, very little is known about the rate of ongoing re-exposure to new traumatic events in drug users. We investigated the rate of traumatic event re-exposure in male and female injecting drug users using syringe exchange services in Baltimore (N = 197). Participants were assessed monthly for traumatic event re-exposure for 16 months. Averaged over the entire follow-up period, 27% of participants were re-exposed to a traumatic event each month and 72% were re-exposed over the 16-month study period. Women were over twice as likely to report any traumatic event re-exposure as men (adjusted odds ratio [AOR] = 2.48; 95% CI = 1.54–3.99), with the specific events of life-threatening illness, death of a loved one, and injury or illness of a loved one being more common in women than men. Traumatic event re-exposure occurs far more often than previously reported, with women injecting drug users at the highest risk. Reassessment of traumatic events may help to identify people most in need and encourage entry into treatment.
- 12 October 2011
- Published by Springer Nature in Journal of Urban Health
- Vol. 89 (1) , 117-128
Traumatic Event Re-exposure in Injecting Drug Users
Drug users have very high rates of lifetime exposure to traumatic events, leading to significant psychiatric complications. In spite of the high rate of lifetime exposure, very little is known about the rate of ongoing re-exposure to new traumatic events in drug users. We investigated the rate of traumatic event re-exposure in male and female injecting drug users using syringe exchange services in Baltimore (N = 197). Participants were assessed monthly for traumatic event re-exposure for 16 months. Averaged over the entire follow-up period, 27% of participants were re-exposed to a traumatic event each month and 72% were re-exposed over the 16-month study period. Women were over twice as likely to report any traumatic event re-exposure as men (adjusted odds ratio [AOR] = 2.48; 95% CI = 1.54–3.99), with the specific events of life-threatening illness, death of a loved one, and injury or illness of a loved one being more common in women than men. Traumatic event re-exposure occurs far more often than previously reported, with women injecting drug users at the highest risk. Reassessment of traumatic events may help to identify people most in need and encourage entry into treatment.